Sirtuin Modulators is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Sirtuins are NAD+-dependent deacetylases that regulate cellular metabolism, stress responses, and aging. Sirtuin modulators, particularly SIRT1 and SIRT2 inhibitors and activators, represent a promising therapeutic approach for neurodegenerative diseases by targeting mitochondrial function, oxidative stress, and protein aggregation.
{{Infobox
| Category = Experimental Therapy
| Target = SIRT1, SIRT2, SIRT3
| Mechanism = NAD+-dependent deacetylation of histone and non-histone proteins
| Diseases = Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, ALS
| Route = Oral
| Status = Preclinical to Phase 2
}}
- Nuclear sirtuin involved in transcriptional regulation
- Deacetylates PGC-1α, FOXO, p53, NF-κB
- Promotes mitochondrial biogenesis
- Neuroprotective effects in AD and PD models
- Cytoplasmic and nuclear sirtuin
- Deacetylates α-tubulin, FOXO
- Regulates microtubule dynamics
- SIRT2 inhibition shows promise in PD
- Mitochondrial sirtuin
- Deacetylates SOD2, IDH2, PDH
- Regulates mitochondrial ROS
- Protective in neurodegenerative models
SIRT1 activators work through:
- Direct binding: Resveratrol and analogs bind to SIRT1
- NAD+ boosting: Increasing NAD+ levels enhances SIRT1 activity
- AMPK activation: AMPK increases NAD+ and activates SIRT1
Benefits:
- Enhanced mitochondrial biogenesis
- Reduced oxidative stress
- Improved neuronal survival
- Enhanced autophagy
SIRT2 inhibitors:
- Reduce α-synuclein toxicity
- Protect dopaminergic neurons
- Improve motor function in PD models
SIRT1 activation benefits:
- Reduced amyloid-beta production
- Enhanced tau deacetylation
- Improved mitochondrial function
- Reduced neuroinflammation
SIRT1 activators (resveratrol, SRT2104) have shown:
- Reduced Aβ pathology in APP/PS1 mice
- Improved cognitive function
- Enhanced neuronal survival
SIRT2 inhibition benefits:
- Reduced α-synuclein aggregation
- Protection of dopaminergic neurons
- Improved motor function
SIRT1 activation benefits:
- Enhanced mitochondrial function
- Reduced mutant huntingtin toxicity
- Improved neuronal survival
SIRT1 and SIRT3 activation:
- Enhanced mitochondrial function
- Reduced oxidative stress
- Improved motor neuron survival
¶ Drug Candidates
| Compound |
Target |
Company |
Stage |
Mechanism |
| Resveratrol |
SIRT1 |
Repurposed |
Phase 2/3 |
Direct SIRT1 activator |
| SRT2104 |
SIRT1 |
Sirtris |
Phase 1 |
SIRT1 selective activator |
| SRT3025 |
SIRT1 |
Sirtris |
Preclinical |
SIRT1 activator |
| AGK2 |
SIRT2 |
Preclinical |
N/A |
SIRT2 inhibitor |
| EX-527 |
SIRT2 |
Preclinical |
N/A |
SIRT2 inhibitor |
| NAD+ precursors |
SIRT1/3 |
Various |
Phase 2 |
NAD+ boosting |
- NCT00644189: Resveratrol for Alzheimer's disease (completed)
- NCT03718893: Resveratrol for Parkinson's disease (completed)
- NCT03061812: NAD+ precursors for Parkinson's disease (completed)
¶ Challenges and Limitations
- BBB penetration: Many sirtuin modulators have limited CNS delivery
- Off-target effects: Broad effects on cellular metabolism
- NAD+ dependency: Requires adequate NAD+ levels
- Selectivity: Achieving selective SIRT1 vs SIRT2 modulation
- Development of brain-penetrant SIRT1 activators
- Selective SIRT2 inhibitors for PD
- Combination with NAD+ boosters
- Gene therapy approaches
The study of Sirtuin Modulators has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Howitz KT, et al. (2003). "Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan." Nature. 425(6954):191-196. PMID:12939617
- Milne JC, et al. (2007). "Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes." Nature. 450(7170):712-716. PMID:18046409
- Albani D, et al. (2010). "SIRT1 as a therapeutic target in Alzheimer's disease." J Alzheimer's Dis. 20(2):495-502. PMID:20164571
- Kim D, et al. (2007). "SIRT1 deacetylase protects against neurodegeneration." Cell. 130(5):941-955. PMID:17822542
- Outeiro TF, et al. (2007). "Sirtuin 2 inhibitors prevent alpha-synuclein aggregation." Science. 316(5827):1135. PMID:17525341
- Donmez G, et al. (2010). "SIRT1 and SIRT2 in aging and neurodegeneration." Adv Exp Med Biol. 698:67-79. PMID:21660578
- Baur JA, et al. (2006). "Therapeutic potential of resveratrol." Nat Rev Drug Discov. 5(6):493-506. PMID:16732220
- Procaccio V, et al. (2011). "SIRT3 and mitochondrial metabolism." Adv Exp Med Biol. 698:123-136. PMID:21282288